These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31130254)

  • 1. Risk factors and outcomes of Clostridium difficile infection in hospitalized patients.
    Lee HY; Hsiao HL; Chia CY; Cheng CW; Tsai TC; Deng ST; Chen CL; Chiu CH
    Biomed J; 2019 Apr; 42(2):99-106. PubMed ID: 31130254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection.
    Lee CC; Lee JC; Chiu CW; Tsai PJ; Ko WC; Hung YP
    Microbiol Spectr; 2021 Oct; 9(2):e0079921. PubMed ID: 34668727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection.
    Stevens VW; Nelson RE; Schwab-Daugherty EM; Khader K; Jones MM; Brown KA; Greene T; Croft LD; Neuhauser M; Glassman P; Goetz MB; Samore MH; Rubin MA
    JAMA Intern Med; 2017 Apr; 177(4):546-553. PubMed ID: 28166328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does Addition of Intravenous Metronidazole to Oral Vancomycin Improve Outcomes in Clostridioides difficile Infection?
    Wang Y; Schluger A; Li J; Gomez-Simmonds A; Salmasian H; Freedberg DE
    Clin Infect Dis; 2020 Dec; 71(9):2414-2420. PubMed ID: 31714955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotics for Treatment of Clostridium difficile Infection in Hospitalized Patients with Inflammatory Bowel Disease.
    Horton HA; Dezfoli S; Berel D; Hirsch J; Ippoliti A; McGovern D; Kaur M; Shih D; Dubinsky M; Targan SR; Fleshner P; Vasiliauskas EA; Grein J; Murthy R; Melmed GY
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5054-9. PubMed ID: 24913174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of Clostridium difficile isolates and the burden of hospital-acquired Clostridium difficile infection in a tertiary teaching hospital in Chongqing, Southwest China.
    Dai W; Yang T; Yan L; Niu S; Zhang C; Sun J; Wang Z; Xia Y
    BMC Infect Dis; 2020 Apr; 20(1):277. PubMed ID: 32293302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole.
    Abujamel T; Cadnum JL; Jury LA; Sunkesula VC; Kundrapu S; Jump RL; Stintzi AC; Donskey CJ
    PLoS One; 2013; 8(10):e76269. PubMed ID: 24098459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy.
    Jardin CG; Palmer HR; Shah DN; Le F; Beyda ND; Jiang Z; Garey KW
    J Hosp Infect; 2013 Sep; 85(1):28-32. PubMed ID: 23834988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
    Johnson S; Louie TJ; Gerding DN; Cornely OA; Chasan-Taber S; Fitts D; Gelone SP; Broom C; Davidson DM;
    Clin Infect Dis; 2014 Aug; 59(3):345-54. PubMed ID: 24799326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of Clostridioides difficile infections treated in a Swiss tertiary care hospital: an observational study.
    Haubitz S; Bartlomé N; Bucheli Laffer E; Spelters C; Fankhauser H; Fux CA
    Swiss Med Wkly; 2020 Jan; 150():w20173. PubMed ID: 31940431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
    Nelson RL; Suda KJ; Evans CT
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
    Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of Oral Vancomycin for Clostridioides difficile Infection and the Risk of Vancomycin-Resistant Enterococci.
    Stevens VW; Khader K; Echevarria K; Nelson RE; Zhang Y; Jones M; Timbrook TT; Samore MH; Rubin MA
    Clin Infect Dis; 2020 Jul; 71(3):645-651. PubMed ID: 31504328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.
    Gentry CA; Campbell DL; Williams RJ
    Int J Antimicrob Agents; 2021 Mar; 57(3):106282. PubMed ID: 33465458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
    Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
    Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology and factors associated with candidaemia following Clostridium difficile infection in adults within metropolitan Atlanta, 2009-2013.
    Vallabhaneni S; Almendares O; Farley MM; Reno J; Smith ZT; Stein B; Magill SS; Smith RM; Cleveland AA; Lessa FC
    Epidemiol Infect; 2016 May; 144(7):1440-4. PubMed ID: 26608090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of adherence to SHEA-IDSA treatment guidelines for Clostridium difficile infection is associated with increased mortality.
    Patel I; Wungjiranirun M; Theethira T; Villafuerte-Galvez J; Castillo N; Akbari M; Alonso CD; Leffler DA; Kelly CP
    J Antimicrob Chemother; 2017 Feb; 72(2):574-581. PubMed ID: 28115504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy.
    Bouza E; Alcalá L; Marín M; Valerio M; Reigadas E; Muñoz P; González-Del Vecchio M; de Egea V
    Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1777-1786. PubMed ID: 28501926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and Risk Factors of Recurrent Clostridioides difficile Infection in Patients With Cirrhosis.
    Phatharacharukul P; Purpura RD; Gandhi D; Xu H; Bickett-Burkhart K; Chalasani N; Fischer M; Orman ES
    Clin Transl Gastroenterol; 2020 Jul; 11(7):e00189. PubMed ID: 32675703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk Factors and Outcomes for Bloodstream Infections Secondary to Clostridium difficile Infection.
    Falcone M; Russo A; Iraci F; Carfagna P; Goldoni P; Vullo V; Venditti M
    Antimicrob Agents Chemother; 2016 Jan; 60(1):252-7. PubMed ID: 26482315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.